الفهرس 
Title pageOnly 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
Acute myeloid leukemia (AML) is one of the most lethal diseases. AML is a bone marrow malignancy that is defined by clonal proliferation and halt of differentiation of myeloid progenitor cells.
The aberrant expression of small nucleolar RNA host gene 5 (SNHG5) was found in many human cancers playing a crucial role in chemotherapy resistance. Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) is a crucial member that is widely expressed in normal human tissues. It was at first thought to be a prognostic indicator of lung cancer metastasis.
The present study aims to evaluate (SNHG5) and (MALAT1) gene expression in de- novo acute myeloid leukemia and their relation with disease response to induction chemotherapy.
This study was conducted on 50 subjects subdivided into 35 newly diagnosed AML patients and 15 patients (diagnosed as hypersplenism) as a control group. The ages of the patient’s group ranged from 19 – 60 years with a mean of 41.83 ± 12.23 and a median of 44 years, and the control group included 10 (66.7 %) males and 5 (33.3%) females whose ages ranged from 21 – 54 years with a mean of 35.93 ± 10.61 and a median of 35 years.
Full history taking, thorough clinical examination, CBC, bone marrow examination at diagnosis, flow-cytometry, liver and renal functions were done to all cases.
SNHG5 expression ranged from (0.22 – 22) with a median of 3.76 (2.56 – 9.54), while in control, SNHG5 expression ranged from (0.0 – 1.83) with a median of 0.51 (0.03 – 1.37). SNHG5 expression in the AML patient group demonstrated statistically significant differences with those of the control group (p <0.001). The cut-off value in cases was (>1.62) by ROC curve.
MALAT1 expression ranged from (0.39 – 77.92) with a median of 14.46 (5.25 – 22.23), while in control, MALAT1 nexpression ranged from (0.66 – 1.56) with a median of 0.91 (0.77 – 1.21). MALAT1 expression in the AML patient group demonstrated statistically significant differences with those of the control group (p <0.001). The cut-off value in cases was (>1.36) by ROC curve.
There were statistically significant relations between SNHG5, MALAT1 and risk stratification in AML cases (p=0.012) and (p=0.027) respectively. In our study, there were statistically negative relations between SNHG5, MALAT1, and post chemotherapy response in AML cases (p=0.001) and (p<0.001) respectively.